IJE Software logoIJEsoft
ServicesPortfolioPricingAboutCase StudyStackNewsBlogPartnerPH NewsMarketsContactGet in touch
← Back to Philippines Business News
Manila Times Business

4BIO Capital leads $60M Series A financing of Oyster Therapeutics (formerly Kesmalea Therapeutics) to advance next-generation targeted protein degraders for Alzheimer’s and other neurodegenerative diseases

Proceeds to advance oral, brain-penetrant tau degrader into clinical development as a novel treatment for tau-driven diseases like Alzheimer’sSeries A led by 4BIO Capital with participation from new investors, including Eli Lilly and Company, alongside existing investorsFinancing supports continued development of proprietary SELFTAC® platform for generating small bifunctional targeted protein degraders with enhanced drug-like propertiesEstablishes collaboration with leading tau researcher Dr. Ca

Context & Analysis

The significance of this type of biotech deal for Philippine readers lies less in the transaction details and more in what it reveals about long-term health-sector pressures. It signals that investors are putting capital into drugs aimed at diseases that are becoming more visible as populations age and diagnostic tools improve. The participation of a large pharmaceutical company in such a round also shows how innovation is increasingly sourced from outside big labs, a pattern that could shape future drug pipelines.

For Philippine businesses, the immediate effect is not a new product on shelves. It is a reminder that global health spending is shifting toward complex, high-value therapies that may eventually reach local markets. Dementia and related conditions are not yet a mass consumer market in the Philippines, but they are increasingly relevant to families, clinics, insurers, and employers. Caregiving, memory screening, home care, nutrition, senior housing, and digital monitoring are adjacent areas where demand can grow as awareness rises. Pharmaceutical distributors and hospital groups may also see pressure to prepare for newer treatments that require specialist prescribing, patient monitoring, or support programs, even if approval and reimbursement take years.

The regulatory path matters just as much as the science. Any eventual therapy would need Philippine Food and Drug Administration review, pricing negotiation, and likely inclusion in public insurance or private plans to be accessible. For local investors, the lesson is to look at infrastructure that supports new drugs—diagnostics, specialty pharmacies, clinical research capacity, and data systems—rather than betting on a single molecule. Clinical trials, if brought here, could also strengthen medical research talent and hospital capabilities.

Consumers should not expect a near-term cure. The more useful signal is that neurodegenerative disease is moving from a caregiving challenge to a technology and capital investment theme, and Philippine health-sector players that build readiness for precision medicines, aging-related care, and long-term patient management may benefit from the next wave of innovation.

Analysis by IJE Software — original commentary on the story above.

This is an excerpt. Read the full article at the original source:

Source: manilatimes.net

More from Manila Times Business

The Eureka Ergonomic Opal Collection Adds Light Oak and Walnut Wood Finishes to Its Executive Standing Desk Line

1h ago

Geekvape launches VPU 2.0 atomisation platform in Dubai

1h ago

Preliminary study finds a clue in the quest to help diagnose CTE in the living

1h ago

Blasts, sirens in Bahrain as Iran announces attack on US base

1h ago

Your Daily Briefing

AI business companion — delivered every morning

Markets, PH news, financial insights, and devotionals — curated by AI and sent at 7 AM PHT. Pick your topics below.

Devotionals
Blog Topics
HR & Workforce
Real Estate & Property
News & Markets

1 topic selected